These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21804605)

  • 41. Fusion partners of NTRK3 affect subcellular localization of the fusion kinase and cytomorphology of melanocytes.
    de la Fouchardière A; Tee MK; Peternel S; Valdebran M; Pissaloux D; Tirode F; Busam KJ; LeBoit PE; McCalmont TH; Bastian BC; Yeh I
    Mod Pathol; 2021 Apr; 34(4):735-747. PubMed ID: 32968185
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.
    Tan AC; Itchins M; Khasraw M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IGF-1R promotes the expression of cyclin D1 protein and accelerates the G1/S transition by activating Ras/Raf/MEK/ERK signaling pathway.
    Tang L; Yang J; Chen J; Yu J; Zhou Q; Lu X; Wang Y
    Int J Clin Exp Pathol; 2017; 10(12):11652-11658. PubMed ID: 31966523
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors.
    Andersson MK; Åman P; Stenman G
    Cells; 2019 Aug; 8(8):. PubMed ID: 31426421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance.
    Lim JKM; Delaidelli A; Minaker SW; Zhang HF; Colovic M; Yang H; Negri GL; von Karstedt S; Lockwood WW; Schaffer P; Leprivier G; Sorensen PH
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9433-9442. PubMed ID: 31000598
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E; Scaltriti M; Drilon A
    Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.
    Tognon CE; Rafn B; Cetinbas NM; Kamura T; Trigo G; Rotblat B; Okumura F; Matsumoto M; Chow C; Davare M; Pollak M; Mayor T; Sorensen PH
    J Biol Chem; 2018 Aug; 293(32):12502-12515. PubMed ID: 29903916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway.
    Werner H; Meisel-Sharon S; Bruchim I
    Mol Cancer; 2018 Feb; 17(1):28. PubMed ID: 29455671
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.
    Krings G; Joseph NM; Bean GR; Solomon D; Onodera C; Talevich E; Yeh I; Grenert JP; Hosfield E; Crawford ED; Jordan RC; van Zante A; Zaloudek C; Shin SJ; Chen YY
    Mod Pathol; 2017 Aug; 30(8):1086-1099. PubMed ID: 28548128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detecting and targetting oncogenic fusion proteins in the genomic era.
    Davare MA; Tognon CE
    Biol Cell; 2015 May; 107(5):111-29. PubMed ID: 25631473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages.
    Lannon CL; Sorensen PH
    Semin Cancer Biol; 2005 Jun; 15(3):215-23. PubMed ID: 15826836
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation.
    Gual P; Le Marchand-Brustel Y; Tanti JF
    Biochimie; 2005 Jan; 87(1):99-109. PubMed ID: 15733744
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.
    Tognon CE; Martin MJ; Moradian A; Trigo G; Rotblat B; Cheng SW; Pollard M; Uy E; Chow C; Carboni JM; Gottardis MM; Pollak M; Morin GB; Sorensen PH
    Oncogene; 2012 Mar; 31(10):1334-40. PubMed ID: 21804605
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
    Tognon CE; Somasiri AM; Evdokimova VE; Trigo G; Uy EE; Melnyk N; Carboni JM; Gottardis MM; Roskelley CD; Pollak M; Sorensen PH
    Cancer Res; 2011 Feb; 71(3):1060-70. PubMed ID: 21148487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.
    Martin MJ; Melnyk N; Pollard M; Bowden M; Leong H; Podor TJ; Gleave M; Sorensen PH
    Mol Cell Biol; 2006 Mar; 26(5):1754-69. PubMed ID: 16478996
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation.
    Morrison KB; Tognon CE; Garnett MJ; Deal C; Sorensen PH
    Oncogene; 2002 Aug; 21(37):5684-95. PubMed ID: 12173038
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.